NeuroSense Issues CEO Letter to Shareholders
NeuroSense Issues CEO Letter to Shareholders NeuroSense Issues CEO Letter to Shareholders PR Newswire CAMBRIDGE, Mass., Aug. 13, 2026 CAMBRIDGE, Mass., Aug. 13, 2026 /PRNewswire/ --NeuroSense Therapeutics Ltd.(NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on...
PR Newswire
NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada
NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada PR Newswire CAMBRIDGE, Mass., Aug. 6, 2026 Final meeting minutes reflect alignment with...
PR Newswire
NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS
NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS PR Newswire CAMBRIDGE, Mass., July 22, 2026 The planned submission follows alignment with Health Canada on the NDS pathway and is supported...
PR Newswire
NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"
NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS" NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS" PR Newswire CAMBRIDGE, Mass., July 6, 2026 Featuring renowned ALS expert Prof...
PR Newswire
NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS
NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark...
PR Newswire
NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease
NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease PR Newswire CAMBRIDGE, Mass., June 25, 2026 PrimeC was...
PR Newswire
EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots
EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots PR Newswire CAMBRIDGE, Mass., June 22, 2026 CAMBRIDGE, Mass., June 22, 2026 /PRNewswire/ -- NeuroSense Therapeutics...
PR Newswire
NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS
NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS PR Newswire CAMBRIDGE, Mass., June 11, 2026 Patent claims cover PrimeC's proprietary formulation, manufacturing process and use in ALSExpands...
PR Newswire
NeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Composition
NeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Composition NeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Composition PR Newswire CAMBRIDGE, Mass., June 9, 2026 Patent Protection Extends Through 2042 following recent U.S., Australia and Brazil...
PR Newswire
NeuroSense Announces Pricing of Insider-Led PIPE Financing
NeuroSense Announces Pricing of Insider-Led PIPE Financing NeuroSense Announces Pricing of Insider-Led PIPE Financing PR Newswire CAMBRIDGE, Mass., April 28, 2026 Financing led by CEO Alon Ben-Noon...
PR Newswire